With apologies for any inconvenience, we are currently experiencing some technical difficulties. Please bear with us.
This bulletin focuses on frailty and end of life and the specific considerations that would apply to this group of patients when reviewing medicines/considering stopping medicines. Medicines that should usually be continued and those with increased potential to cause harm are highlighted in the full bulletin with evidence-based tools to help the review process.
